Dennis Dean, Interim CEO and CFO, discussed the performance and expectations of new centers, focusing on case counts and revenue growth. He also addressed the impact of GLP-1 drugs on skin tightening procedures and new payment options for financing.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing